Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.

By T. Mitsudomi, T. Kosaka, H. Endoh, Y. Horio, T. Hida, S. Mori, S. Hatooka, M. Shinoda, Takashi Takahashi, Yasushi Yatabe. Journal of Clinical Oncology, 2005

960 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants (2005, background): “Sensitive to Gefitinib or Erlotinib Given the association between the presence of activating EGFR mutations and clinical responses to gefitinib or erlotinib in lung adenocarcinoma patients [11,12,13,15], we assessed the ability of these EGFR inhibitors to inhibit anchorage-independent growth of clon”
Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers (2006, background): “tive in patients with deletions than in patients with other types of mutation.(19) Only 3 types of mutant cell lines (in-frame deletions and L858R missense mutation with or without T790M) are available to date.”
EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). (2015, background): “However, adoption of testpatients with EGFR mutation-positive NSCLC of ADC histology (referred to as NSCLC/ADC throughout) to receive personalized treatment with EGFR tyrosine kinase inhibitors (TKIs), which specifically target EGFR oncogenes [9-12], based on the molecular characteristics of their t”